Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions

Charles V. Pollack, Jeffrey I. Weitz, Peter Verhamme et al.|Journal of Thrombosis and Haemostasis|2015

Cited by 2